Search
Mepivacaine
go.drugbank.com/drugs/DB00961ApprovedInvestigationalVet approvedA local anesthetic that is chemically related to bupivacaine but pharmacologically related to lidocaine. It is indicated for infiltration, nerve block, and epidural anesthesia. … Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168)
Products: T. O. MEPIVACAINE 3% PLAIN. SOLUCION INYECTYABLEActivated PI3 kinase delta syndrome
go.drugbank.com/conditions/DBCOND0156285Drugs: LeniolisibSynonyms: Autosomal dominant immunodeficiency due to activated p110-delta syndromeAcute Rheumatic Fever
go.drugbank.com/conditions/DBCOND0063952Synonyms: Acute arthritis due to acute rheumatic feverCytomegalovirus (CMV) Infections
go.drugbank.com/conditions/DBCOND0144080Synonyms: Disease due to CytomegalovirusFerumoxytol
go.drugbank.com/drugs/DB06215ApprovedInvestigationalIn January of 2015, the EMA withdrew marketing authorisation for Rienso (ferumoxytol) due to safety concerns. … [L54501] The drug remains approved in the US, with a new indication being approved in October of 2025 for Ferumoxytol's use as a diagnostic agent for MRI of the brain.
Categories: Compounds used in a research, industrial, or household settingMaribavir
go.drugbank.com/drugs/DB06234ApprovedInvestigational[L39322] Most standard CMV therapies, such as [ganciclovir] or [foscarnet], target CMV DNA polymerase - while generally effective, these medications tend to promote the development of CMV resistance to … Maribavir was approved by the FDA in November 2021, under the name Livtencity (Takeda), for the treatment of resistant CMV infections in post-transplant patients.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseBrexanolone
go.drugbank.com/drugs/DB11859ApprovedInvestigationalAs of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically … /or monoamine oxidase but do not mediate activities directly associated with PPD like natural fluctuations in the levels of endogenous neuroactive steroids like allopregnanolone [F4063].
Glofitamab
go.drugbank.com/drugs/DB16371ApprovedInvestigationalIt has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells. … [L45698,A258488] Glofitamab was approved by Health Canada in March 2023 for the treatment of certain patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), becoming the first CD20
Categories: Bispecific CD20-directed CD3 T Cell EngagerRecombinant stabilized RSV A prefusion F antigen
go.drugbank.com/drugs/DB18713ApprovedInvestigational[L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of
Sofosbuvir
go.drugbank.com/drugs/DB08934ApprovedInvestigationalThis is an important advantage relative to HCV drugs that target other viral enzymes such as the protease, for which rapid development of resistance has proven to be an important cause of therapeutic failure … Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use